{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:52:08Z","timestamp":1772819528860,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1053\/j.ajkd.2011.10.047","type":"journal-article","created":{"date-parts":[[2011,12,28]],"date-time":"2011-12-28T11:08:33Z","timestamp":1325070513000},"page":"670-681","source":"Crossref","is-referenced-by-count":34,"title":["Utilization and Costs of Cardiovascular Disease Medications in Dialysis Patients in Medicare Part D"],"prefix":"10.1053","volume":"59","author":[{"given":"Diane L.","family":"Frankenfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Weinhandl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy L.","family":"St. Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2011.10.047_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.ajkd.2010.10.010","article-title":"USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States","volume":"57","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"suppl 12","key":"10.1053\/j.ajkd.2011.10.047_bib2","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2011.10.047_bib3","first-page":"S1","article-title":"K\/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2011.10.047_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1046\/j.1525-139X.2003.16031.x","article-title":"Uremia-related metabolic cardiac risk factors in chronic kidney disease","volume":"16","author":"Madore","year":"2003","journal-title":"Semin Dial"},{"issue":"2","key":"10.1053\/j.ajkd.2011.10.047_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1525-139X.2003.160271.x","article-title":"Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure","volume":"16","author":"Foley","year":"2003","journal-title":"Semin Dial"},{"issue":"7","key":"10.1053\/j.ajkd.2011.10.047_bib6","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1097\/01.ASN.0000019641.41496.1E","article-title":"Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study","volume":"13","author":"Longenecker","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2011.10.047_bib7","first-page":"1343","article-title":"The renal patient with coronary artery disease: current concepts and dilemmas","volume":"44","author":"Gupta","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1053\/j.ajkd.2011.10.047_bib8","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S0002-9149(98)00205-7","article-title":"Effect of beta-blocker therapy in patients with coronary artery disease in New York Heart Association classes II and III","volume":"81","author":"Haim","year":"1998","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1053\/j.ajkd.2011.10.047_bib9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"issue":"9335","key":"10.1053\/j.ajkd.2011.10.047_bib11","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"issue":"23","key":"10.1053\/j.ajkd.2011.10.047_bib12","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1053\/j.ajkd.2011.10.047_bib13","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"issue":"9364","key":"10.1053\/j.ajkd.2011.10.047_bib14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"9326","key":"10.1053\/j.ajkd.2011.10.047_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"19","key":"10.1053\/j.ajkd.2011.10.047_bib16","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"issue":"12","key":"10.1053\/j.ajkd.2011.10.047_bib17","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"107","author":"Hirsh","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"10.1053\/j.ajkd.2011.10.047_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1523-1755.2004.00473.x","article-title":"Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect?","volume":"65","author":"Ishani","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2008.07.037","article-title":"The ABCs of cardioprotection in dialysis patients: a systematic review","volume":"53","author":"Wetmore","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2011.10.047_bib21","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1053\/j.ajkd.2011.10.047_bib22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"issue":"14","key":"10.1053\/j.ajkd.2011.10.047_bib23","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2011.10.047_bib25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2215\/CJN.07831109","article-title":"Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis","volume":"5","author":"Tai","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/089686080902900514","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Akbari","year":"2009","journal-title":"Perit Dial Int"},{"issue":"21","key":"10.1053\/j.ajkd.2011.10.047_bib27","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/1753944709338339","article-title":"Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis","volume":"3","author":"Suzuki","year":"2009","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2011.10.047_bib30","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis\u2014a randomized study","volume":"21","author":"Takahashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2011.10.047_bib31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/j.ajkd.2005.10.009","article-title":"Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction","volume":"47","author":"Winkelmayer","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2011.10.047_bib32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3317\/jraas.2002.040","article-title":"Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease","volume":"393","author":"McCullough","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib33","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1053\/ajkd.2002.36340","article-title":"ACE inhibitors and survival of hemodialysis patients","volume":"40","author":"Efrati","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2011.10.047_bib34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.CIR.103.7.987","article-title":"Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure","volume":"103","author":"Guerin","year":"2001","journal-title":"Circulation"},{"issue":"22","key":"10.1053\/j.ajkd.2011.10.047_bib35","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1001\/archinte.164.22.2465","article-title":"Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality","volume":"164","author":"Abbott","year":"2004","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1042\/CS20020094","article-title":"Association of calcium channel blockers and mortality in haemodialysis patients","volume":"103","author":"Tepel","year":"2002","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"10.1053\/j.ajkd.2011.10.047_bib37","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1046\/j.1523-1755.2002.00355.x","article-title":"Calcium channel blocker use and mortality among patients with end-stage renal disease","volume":"61","author":"Kestenbaum","year":"2002","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib38","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.ajkd.2007.07.023","article-title":"The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis","volume":"50","author":"Goldfarb-Rumyantzev","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2011.10.047_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2004.09.025","article-title":"HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients","volume":"45","author":"Mason","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2011.10.047_bib40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1523-1755.2002.00109.x","article-title":"HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients","volume":"61","author":"Seliger","year":"2002","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2011.10.047_bib41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2007111207","article-title":"Dilemmas in the management of atrial fibrillation in chronic kidney disease","volume":"20","author":"Reinecke","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2011.10.047_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2215\/CJN.01810407","article-title":"Major bleeding in hemodialysis patients","volume":"3","author":"Holden","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/j.ajkd.2007.06.017","article-title":"Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates","volume":"50","author":"Elliott","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"2-3","key":"10.1053\/j.ajkd.2011.10.047_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-5273(02)00317-0","article-title":"Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?","volume":"87","author":"Vazquez","year":"2003","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1053\/j.ajkd.2011.10.047_bib45","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1681\/ASN.2008080824","article-title":"Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients","volume":"20","author":"Chan","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2011.10.047_bib46","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1681\/ASN.2009030319","article-title":"Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation","volume":"20","author":"Chan","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2011.10.047_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000046216","article-title":"Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation","volume":"21","author":"Wiesholzer","year":"2001","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2011.10.047_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-4-1","article-title":"Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality","volume":"4","author":"Abbott","year":"2003","journal-title":"BMC Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2011.10.047_bib49","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1093\/ndt\/gfp212","article-title":"Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS","volume":"24","author":"Lopes","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2011.10.047_bib50","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s11255-009-9606-1","article-title":"Patterns of cardioprotective medication prescription in incident hemodialysis patients","volume":"41","author":"Sood","year":"2009","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1445-5994.2008.01649.x","article-title":"Medications for the secondary prevention of ischaemic heart disease and heart failure are underutilized in dialysis patients","volume":"38","author":"Ranchord","year":"2008","journal-title":"Intern Med J"},{"issue":"4","key":"10.1053\/j.ajkd.2011.10.047_bib52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/j.ajkd.2006.06.006","article-title":"Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients","volume":"48","author":"Roy","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2011.10.047_bib53","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0828-282X(06)70291-4","article-title":"Cardioprotective medication use in hemodialysis patients","volume":"22","author":"Miller","year":"2006","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.ajkd.2004.08.013","article-title":"Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients","volume":"44","author":"Andreucci","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"14","key":"10.1053\/j.ajkd.2011.10.047_bib55","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/ajhp\/61.14.1473","article-title":"Patterns of antihypertensive medication use in hemodialysis patients","volume":"61","author":"Rahman","year":"2004","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib56","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5414\/CNP61299","article-title":"Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients","volume":"61","author":"Fox","year":"2004","journal-title":"Clin Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2011.10.047_bib57","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/ndt\/gfh280","article-title":"Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider","volume":"19","author":"Manley","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2011.10.047_bib58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1440-1797.2003.00157.x","article-title":"Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001","volume":"8","author":"Chow","year":"2003","journal-title":"Nephrology (Carlton)"},{"issue":"10","key":"10.1053\/j.ajkd.2011.10.047_bib59","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/ndt\/17.10.1819","article-title":"Analysis of drug prescription in chronic haemodialysis patients","volume":"17","author":"Tozawa","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib60","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1046\/j.1523-1755.2002.00638.x","article-title":"Incident acute coronary syndromes in chronic dialysis patients in the United States","volume":"62","author":"Trespalacios","year":"2002","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2011.10.047_bib61","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/ajhp\/57.9.902","article-title":"Comparing medication use in two hemodialysis units against national dialysis databases","volume":"57","author":"Manley","year":"2000","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.1053\/j.ajkd.2011.10.047_bib63","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-9343(01)01068-3","article-title":"Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients","volume":"112","author":"Knoll","year":"2002","journal-title":"Am J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib64","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1046\/j.1523-1755.2002.00324.x","article-title":"Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients","volume":"61","author":"Iseki","year":"2002","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib65","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","article-title":"Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients","volume":"63","author":"Kalantar-Zadeh","year":"2003","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2011.10.047_bib66","first-page":"155","article-title":"Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation","volume":"9","author":"Loghman-Adham","year":"2003","journal-title":"Am J Manag Care"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/2047-783X-14-5-185","article-title":"Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature","volume":"14","author":"Schmid","year":"2009","journal-title":"Eur J Med Res"},{"issue":"6","key":"10.1053\/j.ajkd.2011.10.047_bib68","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib69","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","article-title":"The impact of medication regimen factors on adherence to chronic treatment: a review of literature","volume":"31","author":"Ingersoll","year":"2008","journal-title":"J Behav Med"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2011.10.047_bib70","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease","volume":"41","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2011.10.047_bib71","first-page":"S1","article-title":"K\/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2011.10.047_bib72","first-page":"S1","article-title":"K\/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease","volume":"49","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.whi.2007.03.004","article-title":"Gender disparities in cardiovascular disease care among commercial and MEDICARE managed care plans","volume":"17","author":"Chou","year":"2007","journal-title":"Womens Health Issues"},{"issue":"1","key":"10.1053\/j.ajkd.2011.10.047_bib74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11606-007-0116-5","article-title":"Gender differences in aspirin use among adults with coronary heart disease in the United States","volume":"22","author":"Opotowsky","year":"2007","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.whi.2007.03.001","article-title":"Does quality of care for cardiovascular disease and diabetes differ by gender for enrollees in managed care plans?","volume":"17","author":"Bird","year":"2007","journal-title":"Womens Health Issues"},{"issue":"2","key":"10.1053\/j.ajkd.2011.10.047_bib76","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1525-1497.2005.40155.x","article-title":"Ambulatory hypercholesterolemia management in patients with atherosclerosis","volume":"20","author":"Persell","year":"2005","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib77","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/HPC.0b013e3181b8395d","article-title":"Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry","volume":"8","author":"Kumar","year":"2009","journal-title":"Crit Pathw Cardiol"},{"issue":"3","key":"10.1053\/j.ajkd.2011.10.047_bib78","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF03169170","article-title":"Regional variation in prescribing for chronic conditions among an elderly population using a pharmacy claims database","volume":"175","author":"Naughton","year":"2006","journal-title":"Ir J Med Sci"},{"issue":"2","key":"10.1053\/j.ajkd.2011.10.047_bib79","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0002-8703(03)00237-0","article-title":"Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage","volume":"146","author":"Krumholz","year":"2003","journal-title":"Am Heart J"},{"issue":"5","key":"10.1053\/j.ajkd.2011.10.047_bib80","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2337\/diacare.27.5.1060","article-title":"Are low-income elderly patients at risk for poor diabetes care?","volume":"27","author":"McCall","year":"2004","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1053\/j.ajkd.2011.10.047_bib81","first-page":"59","article-title":"Health status of dually eligible beneficiaries in managed care plans","volume":"25","author":"Lied","year":"2004","journal-title":"Health Care Financ Rev"},{"key":"10.1053\/j.ajkd.2011.10.047_bib82","author":"Kasper"},{"key":"10.1053\/j.ajkd.2011.10.047_bib83","series-title":"USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States","year":"2009"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638611016544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638611016544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T19:34:22Z","timestamp":1713296062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638611016544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0272638611016544"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2011.10.047","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}